**Curriculum Vitae**

Current as of: 6/12/2024

Name: Mary E. Kelley, PhD

Business Address: Rollins School of Public Health

 Emory University

 1518 Clifton Rd, NE

 Atlanta, GA 30322

 Tel: (404) 712-0804

 FAX: (404) 727-1370

 Email: mekelle@emory.edu

 **EDUCATION AND TRAINING**

Undergraduate:

1984 - 1988 University of Pittsburgh Bachelor of Science

 Pittsburgh, PA Psychology/Economics

Graduate:

1992 - 1995 Department of Biostatistics Master of Science

 Graduate School of Public Health

 University of Pittsburgh

 Pittsburgh, PA

1997 – 2003 Department of Biostatistics PhD

 Graduate School of Public Health

 University of Pittsburgh

 Pittsburgh, PA

 **APPOINTMENTS AND POSITIONS**

1988 – 1998 Department of Veterans Affairs Biostatistician

 Medical Center, Pittsburgh, PA

 Schizophrenia Research and

 Treatment Unit (SRTU)

1998 – 2000 Geriatric Research, Education, and Biostatistician

 Clinical Center (GRECC)

 Department of Veterans Affairs VISN-4

1998 – 2004 Center for Research on Healthcare Biostatistician

 University of Pittsburgh

 Pittsburgh, PA

 Center for Health Services Research

 VA Pittsburgh Healthcare System

 Pittsburgh, PA

 Center for Health Equity Research and

 Promotion (CHERP)

 Department of Veterans Affairs VISN-4

1999-2001 R.W. Johnson Statistical consultant

 Pharmaceutical Research Institute

 Raritan, NJ

2000-2004 Mental Illness Research, Education, Biostatistician

 and Clinical Center (MIRECC)

 Department of Veterans Affairs VISN-4

2001-2004 Department of Vascular Surgery Statistical consultant

 University of Pittsburgh Medical Center

 Pittsburgh, PA

2005 – 2007 Department of Psychiatry and Assistant Professor

 Behavioral Sciences

 School of Medicine

 Emory University

 Atlanta GA

2004 – 2008 Department of Biostatistics Research Assistant Professor

 Biostatistics Consulting Center Assistant Director

 Rollins School of Public Health

 Emory University

 Atlanta GA

2009 – 2019 Department of Biostatistics Research Associate Professor

 Rollins School of Public Health

 Emory University

 Atlanta GA

2017 – 2020 Center for Informatics and Director of Biostatistics

 Health Services Research

 Department of Anesthesiology

 School of Medicine

 Emory University

 Atlanta GA

2019 – present Department of Biostatistics Research Professor

 Rollins School of Public Health

 Emory University

 Atlanta GA

**HONORS**

1. Departmental Honors in Psychology, University of Pittsburgh
2. Best Master's Thesis in Biostatistics, Omicron chapter of Delta Omega,

Honors Society of Public Health

**PROFESSIONAL MEMBERSHIPS**

1992 – present American Statistical Association

2003 – present International Biometric Society, Eastern North American Region

2004 – present Delta Omega, Honors Society of Public Health

**PROFESSIONAL ACTIVITIES**

***Teaching:***

**BIOS 732**: **Advanced Numerical Methods**: The course covers topics in traditional numerical analysis specifically relevant to statistical estimation and inference. The topics covered include numerical linear algebra, the root finding problem (maximum likelihood) methods, and both frequentist and Bayesian techniques for further exploration of the likelihood. Spring 2005, 2007, Fall 2010 (dir study), Spring 2012

**BIOS 726: Applied Multivariate Analysis:** The course covers multivariate analysis methods including multivariate regression and ANOVA, data reduction through the use of principal components or factor analysis, multivariate classification and clustering methods. Where applicable, nonparametric and/or categorical adaptations of traditional multivariate normal analyses are also presented. Spring 2015, Fall 2018; Fall 2021

**BIOS 560R: Statistical Methods for Data Analysis:** The course reviews real data examples in public health and discusses the presentation of data for scientific papers. Topics include modeling for different types of dependent variables, repeated measures, predictive models, multiple comparisons and power analysis for grant proposals. Spring 2009.

***Grants:***

**Previously funded*:***

Principal Investigator, Excess Zeros in the Analysis of Ordinal Healthcare Outcomes. VA Mental Illness Research, Education and Clinical Center (MIRECC) seed fund project (Thomas R. Ten Have, mentor). 9/30/01 – 10/01/02.

Co-Investigator, Genetics of Interferon-Alpha-Induced Depression. Natl Alliance for Research on Schizophrenia & Depression (NARSAD). PI: Joe Cubells, MD. 9/15/05-9/14/07.

Co-Principal Investigator, Biostatistics Core, Predictors of Antidepressant Treatment Response: The Emory Cidar. NIMH (P50 MH077083). PI: Charles B. Nemeroff, MD and Helen C. Mayberg, MD. 7/14/06-6/30/12.

Co-Investigator, Imaging predictors of treatment response for depression. NIMH (R01 MH073719). PI: Helen C. Mayberg, MD. 7/26/06-6/30/12.

Co-Investigator, Neural Circuits in Women with Abuse and PTSD. NIMH (R01 MH056120). PI: Douglas Bremner, MD 08/01/06 – 4/30/13.

Co-Investigator, Mechanisms of Depression in CVD. NIH-NHLBI(R01 HL088726). PI: Douglas Bremner, MD. 08/01/06 – 5/31/13.

Co-Investigator, Deep Brain Stimulation for Treatment Resistant Depression. Dana foundation. PI: Helen C. Mayberg, MD. 01/08/07-12/31/07.

Co-Investigator, Treatment for Bipolar Depression: Acute and Prophylactic Efficacy with Citalopram. NIMH (R01 MH078060). Nassir Ghaemi, MD 07/01/07-5/31/08.

Co-Investigator, Predictors of Treatment Response, Relapse and Recurrence in Major Depression.NIMH (R01 MH080880). PI: W. Edward Craighead, PhD. 04/01/08 – 3/31/13.

Co-Investigator, First-Episode Psychosis and Pre-Onset Cannabis Use. NIMH (R01 MH081011). PI: Michael Compton, MD. NIMH. 08/01/08 – 5/31/13.

Co-Investigator, Statistics Core, Emory-GSK-NIMH Collaborative Mood Disorders Initiative. NIMH (U19 MH069056). PI: Helen Mayberg, MD. 05/01/09-5/31/15.

Statistician, Mind Body Interactions in Cardiovascular Disease. NIH-NHLBI (K24 HL077506). PI: Viola Vaccarino, MD. 09/01/09-5/31/14.

Statistician, Public Housing Relocations: Impact on HIV Risk and Drug Use NIDA (R01 DA029513) PI: Hannah Cooper, ScD. 08/01/10-05/31/14

Co-Principal Investigator, Data Management and Statistical Core. Mental Stress Ischemia: Mechanisms and Prognosis. NIH/NHLBI (P01 HL101398). PI: David Sheps, MD. 09/01/10 – 05/31/15.

Co-Investigator, Identifying Biomarkers for Treatment-Resistant Depression. NIMH (R01 MH091100) PI: Paul E. Holtzheimer, MD 04/01/11-3/31/16.

Co-Investigator, Mental Stress and Myocardial Ischemia after MI: Sex Differences and Mechanisms. (R01 HL109413). PI: Viola Vaccarino MD. 04/01/12-03/31/17.

Co-Investigator, Psychophysiological assessment of DBS effects in treatment resistant depression. PI: Helen Mayberg, MD. 04/01/12 – 03/31/14.

Statistician, Place Characteristics and disparities in HIV in IDUs: A multilevel analysis of NHBS. NIDA (R01 DA035101) PI: Hannah Cooper, ScD. 02/01/13 – 01/31/18.

Co-Investigator, The Role of Kynurenine Pathway Activation in Toxoplasma-linked Schizophrenia. VHA (I01 CX000974) PI: Erica Duncan, MD. 07/01/14 – 6/30/18.

Biostatistics Core, Atlanta VA Center for Visual and Neurocognitive Rehabilitation (CVNR). VHA (C2358C). PI: Krish Sathian, MD. 10/01/17-9/30/22.

Co-Investigator, Closed Loop Vagal Stimulation in Posttraumatic Stress Disorder. DARPA (N66001-16-2-4054) PI: Douglas Bremner, MD. 07/21/16-07/20/18.

Co-investigator, Aerobic Exercise for Cognition in Schizophrenia. VHA (1I21RX001897) PI: Erica Duncan, MD. 01/01/16-12/31/18.

Co-Investigator, Testing an Imaging Biomarker for Treatment Stratification in Major Depression. NIMH (R01 MH073719) PI: Helen Mayberg, MD. 04/01/14 – 3/31/20.

Co-Investigator, A Trial of Opening Doors to Recovery. NIMH (R01 MH101307). PI: Michael Compton, MD. NIMH. 06/5/14 – 5/31/20.

**Currently funded:**

Co-Investigator, Biostatistics Core F, Emory/Atlanta Center for AIDS Research (CFAR). NIAID (P30 AI050409-19) PI: Carlos Del Rio, MD. 09/30/02 - 07/31/22.

Co-Investigator, Building a learning healthcare system to understand and improve sepsis outcomes in the VA TeleICU network. VHA (I01 HX002950) . PI: James Blum MD, Heather Reisinger, PhD. 07/01/2020 - 09/31/2024.

Co-Investigator, Assessing an electroencephalogrophy (EEG) biomarker of response to transcranial magnetic stimulator for major depression. VHA (I01 CX002088). PI: Paul Holtzheimer, MD. 07/01/2022 - 06/31/2026.

Co-investigator, Immunometabolic impact of stress hyperglycemia on tuberculosis treatment outcomes and risk of diabetes mellitus. NIAID (R01 AI153152). PI: Matthew Magee, PhD. 12/01/2020 - 11/30/2025.

Co-investigator, A randomized clinical trial examining intranasal oxytocin augmentation of brief couples therapy for veterans with PTSD. VHA (I01 RX004776). PI: Morland, Leslie and Sippel, Lauren. 5/1/2024-4/30/2028.

***Presentations:***

1991 International Congress on Schizophrenia Research, Tucson, AZ. Poster: Deterioration in premorbid functioning: A developmental model of negative symptoms. April.

1992 American Psychiatric Association Annual Meeting, Washington, DC. Poster: Family history of schizophrenia. May.

1993 International Congress on Schizophrenia Research, Colorado Springs, CO. Poster: Longitudinal assessment of deficit syndrome characteristics. April.

1994 Student Symposium of the Pittsburgh Chapter of the American Statistical Association. Presentation: Comparison of competing logistic models using receiver operating characteristic (ROC) curves. February.

1995 International Congress on Schizophrenia Research, Warm Springs, VA. Poster: Prediction of relapse risk over time following haloperidol withdrawal in schizophrenia. April.

1. American College of Neuropsychopharmacology, San Juan, Puerto Rico. Poster: Repeated measures in schizophrenia research: Modeling drug withdrawal effects on plasma HVA and MHPG. December.
2. International Congress on Schizophrenia Research, Colorado Springs, CO. Poster: Repeated measures in schizophrenia research: Modeling drug withdrawal effects on plasma HVA and MHPG. April.

 Society of Biological Psychiatry, San Diego. Oral presentation: Medication effects on negative symptoms in schizophrenia. May.

 American College of Neuropsychopharmacology, Kamuela, Hawaii. Poster: Empirical validation of primary negative symptoms. December.

1. Collegium Internationale Neuropsychopharmacologium (CINP), Glasgow, Scotland. Oral presentation, Young Delegate's Symposium: Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in schizophrenia. July.

2001 American College of Neuropsychopharmacology, Kamuela, Hawaii. Poster: Empirical validation of primary negative symptoms: Longitudinal assessment of clinically stable and exacerbated patients. December.

2003 International Biometrics Society Eastern North American Region (ENAR), Tampa, FL. Oral presentation: Modeling excess zeros in ordinal data. April.

2005 International Congress on Schizophrenia Research, Savannah, GA Poster:

Longitudinal assessment of negative symptoms in schizophrenia: an analytical approach to associations with positive symptoms over time. April

2007 Society of Biological Psychiatry, San Diego. Poster: Resting state brain connectivity as predictors of treatment response in major depression. May.

2011 Society of Biological Psychiatry, San Francisco. Poster: The Illness Density Index (IDI): A measure of treatment success for psychiatric measures. May.

***Editorships:***

2020 - present Statistical Editor, JAMA psychiatry

***Refereed articles:***

# van Kammen DP, Kelley M. Dopamine and norepinephrine activity in schizophrenia: An integrative perspective. Schizophr Res, 4(2):173-191, 1991. PMID:2039760

# Neylan TC, van Kammen DP, Kelley ME, Peters JL. Sleep and schizophrenia on and off haloperidol therapy: Clinically stable vs. relapsed patients. Arch Gen Psychiatry, 49(8):643-649, 1992. PMID:1637254

# Kelley ME, Gilbertson M, Mouton A, van Kammen DP. Deterioration in premorbid functioning in schizophrenia: A developmental model of negative symptoms in drug-free patients. Am J Psychiatry, 149(11):1543-1548, 1992. PMID:1415823

# van Kammen DP, Widerlöv E, Neylan T, Ekman R, Kelley ME, Mouton A, Peters JL. Delta sleep-inducing-peptide-like immunoreactivity (DSIP-LI) and delta sleep in schizophrenic volunteers. Sleep, 15(6):519-525, 1992. Erratum: Sleep, 16(2):198, 1993. PMID: 1475566

# van Kammen DP, Guidotti A, Kelley ME, Gurklis JA, Guarneri P, Gilbertson MW, Yao JK, Peters J, Costa E. CSF diazepam binding inhibitor and schizophrenia: Clinical and biochemical relationships. Biol Psychiatry, 34(8):515-522, 1993. PMID:8274578

# van Kammen DP, Peters JL, Kelley ME, Gilbertson MW, Gurklis JA, O'Connor DT. CSF dopamine ß-hydroxylase in schizophrenia: Associations with premorbid functioning and brain computerized tomography scan measures. Am J Psychiatry, 151(3):372-378, 1994. PMID:8109645

# van Kammen DP, Guidotti A, Neylan T, Guarneri P, Kelley ME, Gurklis J, Gilbertson MW, Peters JL, Costa E. CSF levels of diazepam-binding inhibitor correlate with REM latency in schizophrenia, a pilot study. Eur Arch Psychiatry Clin Neursci, 244(4):216-222, 1994. PMID:7888420

# van Kammen DP, Kelley ME, Gurklis JA, Gilbertson MW, Yao JK, Peters JL. Behavioral vs. biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia. Arch Gen Psychiatry, 52(8):673-678, 1995. PMID: 7543265

# McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, Yao J, Peters JL. Increases in CSF levels of interleukin-2 in schizophrenia: Effects of recurrence of psychosis and medication status. Am J Psychiatry, 152(9):1291-1297, 1995. PMID: 7653683

# van Kammen DP, Kelley ME, Gurklis JA, Gilbertson MW, Yao JK, Condray R, Peters JL. Predicting duration of clinical stability following haloperidol withdrawal in schizophrenic patients. Neuropsychopharmacology, 14(4):275-283, 1996. PMID: 8924195

# Beuger M, van Kammen DP, Kelley ME, Yao J: Dopamine turnover in schizophrenia before and after haloperidol withdrawal: CSF, plasma and urine studies. Neuropsychopharmacology, 15(1):75-86, 1996. PMID:8797194

# van Kammen DP, Kelley ME, Yao JK, Gilbertson MW, Gurklis JA, Inosaka T, Saito H, Peters JL, Sato M. Predicting haloperidol treatment response in chronic schizophrenia. Psychiatry Res, 64(1):47-58, 1996. PMID:8888364

1. Allen DN, Gilbertson MW, van Kammen DP, Kelley ME, Gurklis JA Jr, Barry EJ. Chronic haloperidol treatment does not affect structure of attention in schizophrenia. Schizophr Res, 25(1):53-61, 1997. PMID:9176927
2. Allen DN, Huegel SG, Gurklis Jr JA, Kelley ME, Barry EJ, van Kammen DP: Utility of WAIS-R short forms in schizophrenia. Schizophr Res, 26(2-3):163-172, 1997. PMID:9323347
3. Sanders RD, Forman SD, Pierri JN, Baker RW, Kelley ME, van Kammen DP, Keshavan MS. Inter-rater reliability of the neurological examination in schizophrenia. Schizophr Res, 29(3):287-292, 1998. PMID:9516670
4. van Kammen DP, Poltorak M, Kelley ME, Yao JK, Gurklis JA, Peters JL, Hemperly JJ, Wright RD, Freed WJ. Further studies of elevated cerebrospinal fluid neuronal cell adhesion molecule in schizophrenia. Biol Psychiatry, 43(9):680-686, 1998. PMID:9583002
5. van Kammen DP, Petty F, Kelley ME, Kramer GL, Barry EJ, Yao JK, Gurklis JA, Peters JL. GABA and brain abnormalities in schizophrenia. Psychiatry Res: Neuroimaging, 82(1):25-35, 1998. PMID:9645548
6. Cubells JF, van Kammen DP, Kelley ME, Anderson GM, O’Connor DT, Price LH, Malison R, Rao PA, Kobayashi K, Nagatsu T, Gelernter J. Dopamine β-hydroxylase: Two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Hum Genet, 102(5):533-540, 1998. PMID:9654201
7. Tsai G, van Kammen DP, Chen S, Kelley ME, Grier A, Coyle JT. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol Psychiatry, 44(8):667-674, 1998. PMID:9798069
8. Kelley ME, van Kammen DP, Allen DN. Empirical validation of primary negative symptoms: Independence from effects of medication and psychosis. Am J Psychiatry, 156(3):406-411, 1999. PMID:10080556
9. Kelley ME, Yao JK, van Kammen DP. Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in schizophrenia. Neuropsychopharmacology, 20(6):603-611, 1999. PMID: 10327429
10. Seaton BE, Allen DN, Goldstein G, Kelley ME, van Kammen DP. Relations between cognitive and symptom profile heterogeneity in schizophrenia. J Nerv Ment Dis, 187(7):414-419, 1999. PMID:10426461
11. van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK. Elevated interleukin-6 in schizophrenia. Psychiatry Res, 87(2-3):129-136, 1999. PMID: 10579546
12. Maisto SA, Conigliaro J, McNeil M, Kraemer K, O’Connor M, Kelley ME. Factor structure of the SOCRATES in a sample of primary care patients. Addictive Behaviors, 24(6):879-892, 1999. PMID:10628520
13. Maisto SA, Conigliaro J, McNeil M, Kraemer K, Kelley ME. An empirical investigation of the factor structure of the AUDIT. Psychological Assessment, 12(3):346-353, 2000. PMID:11021159
14. Conigliaro J, Maisto SA, McNeil M, Kraemer K, Kelley ME, Conigliaro R, O’Connor M. Does race make a difference among primary care patients with alcohol problems who agree to enroll in a study of brief interventions? Am J Addict, 9(4):321-330, 2000. PMID:11155785
15. Condray R, Morrow LA, Steinhauer SR, Hodgson M, Kelley M. Mood and behavioral symptoms in individuals with chronic solvent exposure. Psychiatry Res, 97(2-3):191-206, 2000. PMID:11166090
16. Hilton ME, Maisto SA, Conigliaro J, McNeil M, Kraemer K, Kelley ME, Conigliaro R, Samet JH, Larson MJ, Savetsky J, Winter M, Sullivan LM, Saitz R, Weisner C, Mertens J, Parthasarathy S, Moore C, Hunkeler E, Hu T-W, Selby J, Stout RL, Zywiak W, Rubin A, Zwick W, Shepard D. Improving alcoholism treatment across the spectrum of services. Alcohol Clin Exp Res, 25(1):128-135, 2001. PMID:11198708
17. Gordon AJ, Maisto SA, McNeil M, Kraemer K, Conigliaro RL, Kelley ME, Conigliaro J. Three questions can detect hazardous drinkers. J Fam Pract, 50(4):313-320, 2001. PMID:11300982
18. Glassman PA, Good CB, Kelley ME, Bradley M, Valentino M, Ogden J, Kizer KW. Physician perceptions of a national formulary. Am J Manag Care, 7(3):241-251, 2001. PMID:11258142
19. Allen DN, Kelley ME, Miyatake RK, Gurklis Jr. JA, van Kammen DP. Confirmation of a two factor model of premorbid adjustment in males with schizophrenia. Schizophr Bull, 27(1):39-46, 2001. PMID:11215548
20. Lin CJ, Whittle J, Lave JR, Macpherson DS, Brucker N, Kelley ME. Physician satisfaction with medical practice in a VISN. Veterans Health System Journal. 6(5):47-55, 2001.
21. Maisto SA, Conigliaro JC, McNeil M, Kraemer K, Kelley ME. The relationship between eligibility criteria for participation in alcohol brief intervention trials and other alcohol and health-related variables. Am J Addict, 10(3):218-231, 2001. PMID:11579620
22. Maisto SA, Conigliaro J, McNeil M, Kraemer K, Conigliaro RL, Kelley ME. Effects of two types of brief intervention and readiness to change on alcohol use in hazardous drinkers. J Stud Alcohol, 62(5):605-614, 2001. PMID:11702799
23. Muluk SC, Muluk VS, Kelley ME, Whittle JC, Tierney JA, Webster MW, Makaroun MS. Outcome events in patients with claudication: A 15-year study in 2777 patients. J Vasc Surg, 33(2):251-258, 2001. PMID:11198708
24. Aquino R, Johnnides C, Makaroun M, Whittle JC, Muluk VS, Kelley ME, Muluk SC. Natural history of claudication: Long-term serial follow-up study of 1244 claudicants. J Vasc Surg, 34(6):962-970, 2001. PMID:11743546
25. Conigliaro J, Whittle J, Good CB, Skanderson M, Kelley M, Goldberg K. Delay in presentation for cardiac care by race, age, and site of care. Med Care, 40[supp 1]:I-97-I-105, 2002. PMID: 11789636
26. Kraemer KL, Maisto SA, Conigliaro J, McNeil M, Gordon AJ, Kelley ME. Decreased alcohol consumption in outpatient drinkers is associated with improved quality of life and fewer alcohol-related consequences. J Gen Intern Med, 17(5):382-386, 2002. PMID:12047737
27. Gordon AJ, Conigliaro J, Maisto SA, McNeil M, Kraemer KL, Kelley ME. Comparison of consumption effects of brief intervention for hazardous drinking elderly. Substance use and misuse, 38(8):1017-1035, 2003. PMID:12901447
28. Thompson PM, Kelley M, Yao J, Tsai G, van Kammen DP. Elevated cerebrospinal fluid SNAP-25 in schizophrenia. Biol Psychiatry, 53(12):1132-1137, 2003. PMID:
29. Ibrahim SA, Whittle J, Bean-Mayberry B, Kelley ME, Good C, Conigliaro J. Racial/ethnic variations in physician recommendations for cardiac revascularization. Am J Pub Health, 93(10): 1689-1693, 2003. PMID:14534223
30. Bertges DJ, Muluk V, Whittle J, Kelley M, MacPherson DS, Muluk SC. Relevance of carotid stenosis progression as a predictor of ischemic neurological outcomes. Arch Intern Med, 163(19):2285-2289, 2003. PMID:14581246
31. Raman KG, Layne S, Makaroun MS, Kelley ME, Rhee RY, Tzeng E, Muluk VS, Muluk SC. Disease progression in contralateral carotid artery is common after endarterectomy. J Vasc Surg, 39(1):52-57, 2004. PMID:14718813
32. Glassman PA, Good CB, Kelley ME, Bradley M, Valentino M. Physician satisfaction with formulary policies: Is it access to formulary or nonformulary drugs that matters most? Am J Manag Care, 10(3):209-216, 2004. PMID:15032258
33. Fultz SL, Good CB, Kelley ME, Fine MJ. Increased diabetes-related pharmaceutical costs are not associated with improved glycemic control at three VA outpatient settings. Pharmacy & Therapeutics, 29(8):500-506, 2004.
34. Zahid M, Sonel AF, Kelley ME, Wall L, Whittle J, Fine MJ, Good CB. Effect of both elevated troponin-I and peripheral white blood cell count on prognosis in patients with suspected myocardial injury. Am J Cardiol, 95(8):970-972, 2005. PMID:15820165
35. Kerendi F, Halkos ME, Kin H, Corvera JS, Brat DJ, Wagner MB, Vinten-Johansen J, Zhao Z-Q, Forbess JM, Kanter KR, Kelley ME, Kirshbom PM. Upregulation of hypoxia inducible factor is associated with attenuation of neuronal injury in neonatal piglets undergoing deep hypothermic circulatory arrest. J Thorac Cardiovasc Surg, 130(4):1079-1085, 2005. PMID:16214523
36. Jones A, Kwoh CK, Kelley ME, Ibrahim SA. Racial disparity in knee arthroplasty utilization in the Veterans Health Administration. Arthritis and Rheumatism, 53(6):979-981, 2005. PMID:16342110
37. Mays DM, Gordon AJ, Kelley ME, Forman SD. Violent criminal behavior and perspectives on treatment of criminality in opiate treatment. Substance Abuse, 26(2):33-42, 2005.

1. Rogers AJ, Greenwald MH, DeGuzman MA, Kelley ME, Simon HK. A randomized, controlled trial of sucrose analgesia in infants younger than 90 Days of age who require bladder catheterization in the pediatric emergency department. Academic Emergency Medicine, 13(6): 617-622, 2006. PMID:16636358
2. Greenspan AI, Wolf SL, Kelley ME, O’Grady M. Tai chi and perceived health status in older adults who are transitionally frail: A randomized controlled trial. Physical Therapy, 87(5): 525-535, 2007. PMID:17405808
3. Hravnak M, Whittle J, Kelley ME, Sereika S, Good CB, Ibrahim SA, Conigliaro J. Symptom expression in coronary heart disease and revascularization recommendations for black and white patients. Am J Pub Health, 97(9): 1701-1708, 2007. PMID:17329655
4. Whittle J, Conigliaro J, Good CB, Kelley ME, Skanderson M. Understanding of the benefits of coronary revascularization procedures among patients who are offered such procedures. Am Heart J, 154(4):662-668, 2007. PMID:17892988
5. Bremner JD, Vermetten E, Kelley ME. Cortisol, dehydroepiandrosterone, and estradiol measured over 24 hours in women with childhood sexual abuse-related posttraumatic stress disorder (PTSD). J Nerv Ment Dis, 195(11):919-927, 2007. PMID:18000454
6. Ghaemi SN, Gilmer WS, Goldberg JF, Zablotsky B, Kemp DE, Kelley ME, Bauer AD, Fleck J, Filkowski MM, Stan VA, Dunn RT. Divalproex in the treatment of acute bipolar depression: A preliminary double blind, randomized, placebo-controlled pilot study. J Clin Psychiatry. 68(12):1840-1844, 2007. PMID:18162014
7. Goldberg JF, Kelley ME, Rosenquist KJ, Hsu DJ, Filkowski MM, Ghaemi SN. Effectiveness of quetiapine in rapid cycling bipolar disorder: A preliminary study. J Aff Disorders 105(1-3): 305-310, 2008. PMID: 17550787
8. Holtzheimer III, PE, Meeks TW, Kelley ME, Mufti M, Young R, McWhorter K, Vito N, Chismar R, Quinn S, Dey S, Byrd EH, McDonald WM. A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. Int J Geriatr Psychiatry 23(6):625-631, 2008. PMID:18058832; PMC4423545
9. Kelley ME, Anderson SJ. Zero inflation in ordinal data: Incorporating susceptibility to response through the use of a mixture model. Statist Med, 27(18):3674-3688, 2008. PMID:18351711; PMC2572084
10. Kelley ME, Haas GL, van Kammen DP. Longitudinal progression of negative symptoms in schizophrenia: A new look at an old problem. Schizophr Res, 105(1-3):188-196, 2008. PMID:18619815; PMC2600772
11. James GA, Kelley ME, Craddock RC, Holtzheimer PE, Dunlop BW, Nemeroff CB, Mayberg HS, Hu XP. Exploratory structural equation modeling of resting-state fMRI: Applicability of group models to individual subjects. Neuroimage, 45(3):778-787, 2009. PMID:19162206; PMC2653594
12. Vaccarino V, Bremner JD, Kelley ME. JUPITER: a few words of caution. Circ Cardiovasc Qual Outcomes, 2(3):286-288, 2009. PMID:20031850; PMC2798141
13. Compton MT, Kelley ME, Ramsay CE, Pringle M, Goulding SM, Esterberg ML, Stewart T, Walker EF. Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. Am J Psychiatry, 166(11):1251-1257, 2009. PMID:19797432; PMC3662470.
14. Ghaemi SN, Ostacher MM, El-Mallakh RS, Borrelli D, Baldassano CF, Kelley ME, Filkowski MM, Hennen J, Sachs GS, Goodwin FK, Baldessarini RJ. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry, 71(4):372-380, 2010. PMID: 20409444
15. Gerardi M, Rothbaum BO, Astin MC, Kelley M. Cortisol response following exposure treatment for PTSD in rape victims. J Aggress Maltreat Trauma, 19(4):349-356, 2010. PMID: 20526437; PMC2880549
16. Holzheimer III PE, McDonald WM, Mufti M, Kelley ME, Quinn S, Corso G, Epstein CM. Accelerated repetitive transcranial magnetic stimulation for treatment-resistant depression. Depression and anxiety. 27(10):960-963, 2010. PMID:20734360; PMC3020591
17. Compton MT, Kelley ME, Lloyd RB, McClam T, Ramsay CE, Haggard PJ, Augustin S. Predictors of the discharge dosage of an atypical antipsychotic agent among treatment-naïve first-episode patients in naturalistic, public-sector settings. J Clin Psychopharmacology, 31:10-15, 2011. PMID: 21192136
18. Hasenkemp W, Kelley M, Egan G, Green A, Wilcox L, Boshoven W, Lewison B, Duncan E. Lack of relationship between acoustic startle and cognitive variables in schizophrenia and control subjects. Psychiatry Res, 187(3):324-328, 2011. PMID: 21397338; PMC3078961
19. Holstad MM, Diiorio C, Kelley ME, Resnicow K, Sharma S. Group motivational interviewing to promote adherence to antiretroviral medications and risk reduction behaviors in HIV infected women. AIDS Behav, 15(5):885-896, 2011. PMID: 21165692; PMC3112287
20. Katz ER, Stowe ZN, Newport DJ, Kelley ME, Pace TW, Cubells JF, Binder EB. Regulation of mRNA expression encoding chaperone and co-chaperone proteins of the glucocorticoid receptor in peripheral blood: Association with depressive symptoms during pregnancy. Psychol Med, 42(5) 943-56, 2012. PMID:21995950
21. Dunlop BW, Kelley ME, Mletzko TC, Velasquez CM, Craighead WE, Mayberg HS. Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder. J Psychiatr Res, 201:46(3) 375-81, 2012. PMID:22118808; PMC3288535
22. Holtzheimer III PE, Kelley ME, Gross RE, Filkowski MM, Garlow SJ, Barrocas A, Wint D, Craighead MC, Kozarsky J, Chismar R, Moreines JL, Mewes K, Riva Posse P, Gutman DA, Mayberg HS. Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch Gen Psychiatry, 69(2):150-8, 2012. PMID:22213770; PMC4423545
23. Kelley ME, Franco AR, Mayberg HS, Holtzheimer III, PE. The Illness Density Index (IDI): A longitudinal measure of treatment efficacy. Clinical Trials, 9(5):596-604, 2012. PMID: 22801557; PMC3742034
24. Dunlop BW, Binder EB, Cubells JF, Goodman MG, Kelley ME, Kinkead B, Kutner M, Nemeroff CB, Newport DJ, Owens MJ, Pace TWW, Ritchie JC, Rivera VA, Westen D, Craighead WE, Mayberg HS. Predictors of remission in depression to individual and combined treatments (PReDICT): Study protocol for a randomized controlled trial. Trials, 13:106, 2012. PMID:22776534; PMC3539869
25. Kelley ME, White L, Compton MT, Harvey PD. Subscale structure for the Positive and Negative Syndrome Scale (PANSS): A proposed solution focused on clinical validity. Psychiatry Research, 205(1-2):137-142, 2013. PMID:22974521; PMC3532554
26. Broussard B, Kelley ME, Ramsay Wan C, Cristofaro SL, Crisafio A, Haggard PJ, Myers NL, Reed T, Compton MT. Demographic, social-environmental and substance-related predictors of duration of untreated psychosis (DUP), Schizophr Res, 148:93-98, 2013. PMID:23746486; PMC3732564
27. Vaccarino V, Kondwani KA, Kelley ME, Murrah NV, Boyd L, Ahmed Y, Meng YX, Gibbons GH, Hooper WC, De Staercke C, Quyyumi AA. Effect of meditation on endothelial function in black americans with metabolic syndrome: a randomized trial. Psychosom Med, 75(6):591-599, 2013. PMID:23788695; PMC3774317
28. McGrath CL, Kelley ME, Holtzheimer III PE, Dunlop BW, Craighead WE, Franco AR, Craddock RC, Mayberg HS. Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry, 70(8):821-829, 2013. PMID:23760393; PMC4413467
29. Cooper HL, Bonney LE, Ross Z, Karnes C, Hunter-Jones J, Kelley ME, Rothenberg R. The Aftermath of Public Housing Relocation: Relationship to Substance Misuse Drug and Alcohol Dependence. Drug and Alcohol Dependence, 131(1)37-44, 2013. PMID:23850372; PMC3786035
30. Compton MT, Kelley ME, Ionescu DF. Subtyping first-episode nonaffective psychosis using four early-course features: Potentially useful prognostic information at initial presentation. Early Intervention in Psychiatry, 8(1):50-58, 2014. PMID: 23343467; PMC3672389
31. Aponte-Rivera V, Dunlop BW, Ramirez C, Kelley ME, Schneider R, Blastos B, Larson J, Mercado F, Mayberg H, Craighead WE. Enhancing Hispanic Participation in Mental Health Clinical Research: Development of a Spanish-speaking Depression Research Site. Depress Anxiety, 31(3): 258-267, 2014. PMID:23959771; PMC4379482
32. Cooper HLF, Hunter-Jones J, Kelley ME, Karnes C, Haley D, Ross Z, Rothenberg R, Bonney LE. The Aftermath of Public Housing Relocations: Relationships between Changes in Local Socioeconomic Conditions and Depressive Symptoms in a Cohort of Adult Relocaters. J Urban Health, 91(2): 223-241, 2014. PMID:24311024; PMC3978147
33. McGrath CL, Kelley ME, Dunlop BW, Holtzheimer III PE, Craighead WE, Mayberg HS. Pretreatment Brain States Identify Likely Nonresponse to Standard Treatments for Depression. Biol Psychiatry, 76(7): 527-535, 2014. PMID:24462230; PMC4063885.
34. Moreines JL, McClintock SM, Kelley ME, Holtzheimer PE, Mayberg HS. Neuropsychological Function Before and After Subcallosal Cingulate Deep Brain Stimulation in Patients with Treatment-Resistant Depression. Depress Anxiety, 31(8):690-698, 2014. PMID: 24753183; PMC4226070
35. Dunlop BW, Rothbaum BO, Binder EB, Duncan E, Harvey PD, Jovanovic T, Kelley ME, Kinkead B, Kutner M, Iosifescu DV, Mathew SJ, Neylan TC, Kilts CD, Nemeroff CB, Mayberg HS. Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttramatic stress disorder: study protocol of a randomized trial. Trials, 15(1): 240, 2014. PMID:24950747; PMC4082482
36. Kaye JL, Dunlop BW, Iosifescu DV, Mathew SJ, Kelley ME, Harvey PD. Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: Examining the convergence of performance-based measures and self-reports. J Psychiatr Res. 57: 51-57, 2014. PMID: 24974001; PMC4127348
37. Choi KS, Holtzheimer P, Franco A, Kelley ME, Dunlop BD, Hu X, Mayberg HS. Reconciling variable findings of white matter integrity in major depressive disorder. Neuropsycopharmacology, 39(6):1332-1339, 2014. PMID:24352368; PMC3988550
38. Cooper HL, Haley DF, Linton S, Hunter-Jones J, Martin M, Kelley ME, Karnes C, Ross Z, Adimora AA, del Rio C, Rothenberg R, Wingood GM, Bonney LE. Impact of housing relocations: are changes in neighborhood conditions related to STIs among relocaters? Sex Transm Dis, 41(10):573-579, 2014. PMID: 25211249; PMC4163933
39. Cooper HL, Linton S, Haley DF, Kelley ME, Dauria EF, Karnes CC, Ross Z, Hunter-Jones J, Renneker KK, del Rio C, Adimora A, Wingood G, Rothenberg R, Bonney LE. Changes in exposure to neighborhood characteristics are associated with sexual network characteristics in a cohort of adults relocating from public housing. AIDS behav,19(6):1016-30, 2014. PMID: 25150728; PMC4339671
40. Pimple P, Shah A, Rooks C, Bremner JD, Nye J, Ibeanu I, Murrah N, Shallenberger L, Kelley M, Raggi P, Vaccarino V. Association between anger and mental-stress induced myocardial ischemia. Am Heart J, 169(1):115-121, 2015. PMID: 25497256. PMC4268485.
41. Linton S, Cooper HLF, Kelley ME, Karnes CC, Ross Z, Wolfe ME, Friedman SR, Des Jarlais D, Semaan S, Tempalski B, Finlayson T, Sionean C, DiNenno E, Wejnert C, Paz-Bailey G, for the National HIV Behavioral Surveillance Study Group. HIV Infection Among People Who Inject Drugs in the United States: Geographically Explained Variance Across Racial and Ethnic Groups. A J Public Health.105(12): 2457-2465, 2015. PMID: 26469638; PMC4638266.
42. Dunlop BW, Kelley ME, McGrath CL, Craighead WE, Mayberg HS. Preliminary Findings Supporting Insula Metabolic Activity as a Predictor of Outcome to Psychotherapy and Medication Treatments for Depression. J Neuropsychiatry Clin Neurosci. 27(3):237-9, 2015. PMID: 26067435; PMC4788472
43. Compton MT, Kelley ME, Pope A, Smith K, Broussard B, Reed TA, DiPolito JA, Druss BG, Li C, Lott Haynes N. [Opening Doors to Recovery: Recidivism and Recovery Among Persons With Serious Mental Illnesses and Repeated Hospitalizations.](http://www.ncbi.nlm.nih.gov/pubmed/26467907) Psychiatr Serv. 67:169-175, 2016. PMID: 26467907.
44. Cooper HLF, Linton S, Kelley ME, Ross Z, Wolfe ME, Chen Y, Zlotorzynska M, Hunter-Jones J, Friedman SR, Des Jarlais DC, Semaan S, Tempalski B, DiNenno E, Broz D, Wejnert C, Paz-Bailey G, for the National HIV Behavioral Surveillance Study Group. Racialized Risk Environments in a Large Sample of People who Inject Drugs In the United States. International Journal of Drug Policy. 27:43-55, 2016. PMID: 26342272; PMC4715941
45. Kelley ME, Wan CR, Broussard B, Crisafio A, Cristofaro S, Johnson S, Reed TA, Amar P, Kaslow NJ, Walker EF, Compton MT. Marijuana use in the immediate 5-year period is associated with increased risk of onset of schizophrenia and related psychotic disorders. Schizophr Res, 171:62-67, 2016. PMID: 26785806; PMC4929616.
46. Kalokhe AS, Stephenson R, Kelley ME, Dunkle KL, Paranjape A, Solas V, Karve L, del Rio C, Sahay S. The development and validation of the Indian Family Violence and Control Scale. PloS One, 11(1):e0148120. 2016. PMID:26824611; PMC4732749.
47. Cooper HLF, Linton S, Kelley ME, Ross Z, Wolfe ME, Chen Y-T, Zlotorzynska M, Hunter-Jones J, Friedman SR, Des Jarlais DC, Tempalski B, DiNenno E, Broz D, Wejnert C,  Paz-Bailey G, for the National HIV Behavioral Surveillance Study Group. Risk environments, race/ethnicity, and HIV status in a large sample of people who inject drugs in the United States. *PLOS One*. 11(3):e0150410, 2016. PMID:26974165; PMC4790920.
48. Linton SL, Cooper HLF, Kelley ME, Karnes CC, Ross Z, Wolfe ME, Chen Y-T, Friedman SR, Des Jarlais DC, Semaan S, Tempalski B, Sionean C, DiNenno E, Wejnert C, Paz-Bailey G, of the National HIV Behavioral Surveillance Study Group. The association of place characteristics with HIV and HCV risk behaviors among racial/ethnic groups of people who inject drugs in the United States. Ann Epidemiol. 26(9):619-630, 2016. PMID: 27576908; PMC5110217.
49. Kalokhe AS, Ibegbu CC, Kaur SP, Amara RR, Kelley ME, del Rio C, Stephenson R. Intimate partner violence in associated with increased CD4+ T-cell activation among HIV-negative high-risk women. Pathog Immun. 1(1):193-213, 2016. PMID: 27668294; PMC5034930.
50. Dunlop BW, Kelley ME, Aponte-Rivera V, Mletzo-Crowe T, Kinkead B, Ritchie JC, Nemeroff CB, Craighead WE, Mayberg HS, for the PReDICT Team. Effects of patient preferences on outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study. Am J Psychiatry. 174(6):546-556, 2017. PMID: 28335624; PMC6690210.
51. Dunlop BW, Rajendra JK, Craighead WE, Kelley ME, McGrath CL, Choi KS, Kinkead B, Nemeroff CB, Mayberg HS. Functional connectivity of the subcallosal cingulate cortex and outcomes to treatment with cognitive behavior therapy and antidepressant medication for major depressive disorder. Am J Psychiatry. 174(6):533-545, 2017. PMID: 28335622; PMC5453828.
52. Linton SL, Cooper HL, Kelley ME, Karnes CC, Ross Z, Wolfe ME, Friedman SR, Jarlais DD, Semaan S, Tempalski B, Sionean C, DiNenno E, Wejnert C, Paz-Bailey G, of the National HIV Behavioral Surveillance Study Group. Cross-sectional association between ZIP code-level gentrification and homelessness among a large community-based sample of people who inject drugs in 19 US cities. BMJ Open. 7(6):e013823, 2017. PMID: 28637724; PMC5541298.
53. Pauselli L, Birnbaum ML, Vazquez J, Paolini E, Kelley ME, Broussard B, Compton MT. Demographic and socioenvironmental predictors of premorbid marijuana use among patients with first-episode psychosis. Schizophr Res. 197:544-549, 2018. PMID: 29397281; PMC6068011.
54. Kelley ME, Dunlop BW, Nemeroff CB, Lori A, Carillo-Roa T, Binder EB, Kutner MH, Aponte Rivera V, Craighead WE, Mayberg HS. Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse. Depression and Anxiety. 35(10):992-1000, 2018. PMID: 30260539; PMC6662579.
55. Tempalski B, Cooper HLF, Kelley ME, Linton SL, Wolfe ME, Chen YT, Ross Z, Des Jarlais DC, Friedman SR, Williams LD, Semaan S, DiNenno E, Wejnert C, Broz D, Paz-Bailey G, for the National HIV Behavioral Surveillance Study Group. Identifying which place characteristics are associated with the odds of recent HIV testing in a large sample of people who inject drugs in 19 US metropolitan areas. AIDS & Behavior. 23(2):318-335, 2019. PMID: 29971735; PMC6318077.
56. Stentz MJ, Kelley ME, Jabaley CS, O’Reilly-Shah V, Groff RF, Moll V, Blum JM. Trends in extracorporeal membrane oxygenation growth in the United States, 2011-2014. ASAIO J. 65(7):712-717, 2019. PMID:30247176.
57. Philip NS, Aiken EA, Kelley ME, Burch W, Waterman L. Holtzheimer PE. Synchronized transcranial magnetic stimulation for posttraumatic stress disorder and comorbid major depression. Brain Stimulation. 12(5):1335-1337, 2019. PMID:31204205.
58. Crowell AL, Riva-Posse P, Holtzheimer PE, Garlow SJ, Kelley, ME, Gross RE, Denison L, Quinn S, Mayberg HS. Long-term outcomes of subcallosal cingulate deep brain stimulation for treatment-resistant depression. Am J Psychiatry, 176(11):949-956, 2019. PMID: 31581800.
59. Pope LG, Manseau MW, Kelley ME, Compton MT. Symptomatology and neurocognition among first-episode psychosis patients with and without cannabis use in the three months prior to first hospitalization. Schizophr Res. 228:83-88, 2021. PMID: 33434738.
60. Kelley ME, Choi KS, Rajendra JK, Craighead WE, Rakofsky JJ, Dunlop BW, Mayberg HS. Establishing evidence for clinical utility of a neuroimaging biomarker in major depressive disorder: Prospective testing and implementation challenges. Biol Psychiatry. 90(4):236-242, 2021. PMID: 33896622; PMC8324510.
61. Pope LG, Ashekun O, Zern A, Kelley ME, Compton MT. Associations between childhood adolescence adversity and risk for arrest among patients with first-episode psychosis. Psychiatr Serv. 72(7):826-829, 2021. PMID: 33820443.
62. Zanoni BC, Archary M, Sibaya T, Musinguzi N, Kelley ME, McManus S, Haberer JE: Development and validation of the HIV adolescent readiness for transition scale (HARTS) in South Africa. J Int AIDS Soc. 24(7):e25767. 2021. PMID:34235876; PMC8264413.
63. Langlois S, Zern A, Kelley ME, Compton MT. Adversity in childhood/adolescence and premorbid tobacco, alcohol, and cannabis use among first-episode psychosis patients. Early Intervention in Psychiatry. 15(5):1335-1342, 2021. PMID:33289325.
64. Conroy SK, Malloy S, Kelley ME, Filkowski MM, Trimble RM, Pirtle ME, Maher A, Dreyer-Oren S, Doucette W, Roth RM, Aronson JP, Roberts DW, Choi KS, Mayberg HS, Holtzheimer PE. Left versus right subcallosal cingulate deep brain stimulation for treatment-resistant depression. Personalized Medicine in Psychiatry.25: 2021.DOI: <https://doi.org/10.1016/j.pmip.2021.100069>.
65. Compton MT, Kelley ME, Anderson S, Ellis S, Graves J, Broussard B, Pauselli L, Zern A, Pope L, Johnson M, Lott Haynes N. Opening Doors to Recovery: A randomized, controlled trial of a recovery-oriented community navigation service for individuals with serious mental illnesses and repeated hospitalizations. J Clin Psychiatry, 84(2):22m14498, 2023. PMID:36652687; PMC10201887
66. Sippel, LM, Wachsman, T, Kelley, ME, Knopp, KC, Khalifian, CK. Maglione, JE, Glynn, S, Macdonald, A, Monson, C, Flanagan, JC, Holtzheimer, PE, Morland, LA. Design of a randomized clinical trial of brief couple therapy for PTSD augmented with intranasal oxytocin. *Contemporary Clinical Trials,* in press.

# ***Book chapters:***

1. van Kammen DP, Peters JL, O'Connor DT, Gelernter J, Ekman R, Widerlöv E, Guidotti A, Perel J, Kelley ME, Beuger M, Gurklis J. CSF peptides and long-term neuroleptic treatment in schizophrenia: Effects of haloperidol withdrawal and relapse. In: Biological Psychiatry, Volume 1. Racagni G, Brunello N, Fukuda T. (eds.), Elsevier Science Publishers, 580-582, 1991.
2. van Kammen, DP, Mouton, A, Kelley, M, Breeding, W, Peters, J. Explorations of dopamine and noradrenaline activity and negative symptoms in schizophrenia: Concepts and controversies. In: Negative versus Positive Schizophrenia. Marneros, A, Andreasen, NC, Tsuang, MT. (eds.), Springer-Verlag Berlin Heidelberg, 317-340, 1991.
3. van Kammen DP, McAllister C, Yao JK, Kelley ME, Gilbertson MW, Gurklis JA, Peters JL. A clinical and biochemical model of relapse prediction in schizophrenia: A role for CSF interleukin 2? In: The Biology of Schizophrenia. Moroji T, Yamamoto K, eds. New York, Elsevier, pp 219-229, 1994.
4. McAllister CG, van Kammen DP, Kelley ME. Relapse prediction in schizophrenia: from monoamines to cytokines. In: Adv Biol Psychiatry, vol 18: Immunological Alterations in Psychiatric Diseases. Henneberg AE, Kaschka WP, eds. Basel, Karger, pp 44-49, 1997.
5. van Kammen DP, McAllister CG, Kelley ME. Relationship between immune and behavioral measures in schizophrenia. In: Current update in psychoimmunology. Key topics in brain research. Wieselmann G, ed. New York, Springer-Verlag, pp 51-55, 1997.
6. van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK. Methodological concerns in the study of the immune system in schizophrenia. In: Psychiatry, Psychoimmunology, and Viruses. Müller, N, ed. New York, Springer-Verlag Wien, pp 63-69, 1999.
7. Kelley, ME. Principal Component Analysis. In: The Corsini Encyclopedia of Psychology, 4th edition, Vol. 3. Weiner IB, Craighead WE, eds. Hoboken, John Wiley & Sons, p. 1291, 2010.